COMPANY
Tonix Pharmaceuticals, Inc.
FDA-approved therapeutic company Clinical Phase 3
Since the raise (Dec 29, 2025): 11 of 11 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Director, Compliance | Berkeley Heights, NJ | Oct 9, 2026 | Oct 10, 2026 |
| Director, KOL Engagement | United States | Oct 9, 2026 | Oct 10, 2026 |
| Regional Sales Director - Florida | Florida | Oct 8, 2026 | Oct 8, 2026 |
| Senior Director, Regulatory Affairs – Infectious Disease | Berkeley Heights, NJ or Frederick, MD | Sep 22, 2026 | Oct 5, 2026 |
| Senior Clinical Project Manager | Berkeley Heights, NJ | Sep 21, 2026 | Oct 5, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (11 open jobs at last check). source ↗
- Trial start Phase 2: A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) source ↗
- Raise Follow-on offering — Registered direct: $20M (total, as published), announced Dec 29, 2025. Source: company release on GlobeNewswire. source ↗
- Trial start 1: A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants source ↗
- FDA FDA Original approval: TONMYA (cyclobenzaprine hydrochloride) — NDA219428, Aug 15, 2025. Applicant at approval: Tonix Pharmaceuticals, Inc. source ↗
- Trial start Phase 2: Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) source ↗
- Trial start 1: A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy S source ↗
- Trial start Phase 2: Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) source ↗
- Trial start Phase 2: A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine source ↗
- Trial start Phase 2: Safety and Efficacy Study of TNX-102 SL in Participants With PTSD source ↗
- Trial start 2: A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection source ↗
- Trial start 3: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia source ↗
- Trial start Phase 1: A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy J source ↗
- Trial start Phase 1: Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens source ↗
- Trial start Phase 2: An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male source ↗
- Trial start 3: A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia source ↗
- Trial start Phase 3: A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia source ↗
- Trial start Phase 1: Dose-Proportionality and Food Effect Study of TNX-102 SL source ↗
- Trial start 3: A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD source ↗
- Trial start Phase 3: A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD source ↗
- Trial start Phase 1: Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules source ↗
- Trial start Phase 3: 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients source ↗
- Trial start Phase 3: Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD source ↗
- Trial start Phase 3: Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia source ↗
- Trial start Phase 1: Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. source ↗
Upcoming milestones
- 2028-02 (ESTIMATED) · Phase 2 · A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) · NCT07621237
Open jobs 11
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Director, Compliance | Berkeley Heights, NJ | Oct 9, 2026 | Oct 10, 2026 | Senior |
| Director, KOL Engagement | United States | Oct 9, 2026 | Oct 10, 2026 | Senior |
| Regional Sales Director - Florida | Florida | Oct 8, 2026 | Oct 8, 2026 | Senior |
| Senior Director, Regulatory Affairs – Infectious Disease | Berkeley Heights, NJ or Frederick, MD | Sep 22, 2026 | Oct 5, 2026 | Senior |
| Senior Clinical Project Manager | Berkeley Heights, NJ | Sep 21, 2026 | Oct 5, 2026 | Senior |
| Senior Internal Auditor - SOX Compliance | Berkeley Heights, NJ | Sep 16, 2026 | Oct 5, 2026 | Senior |
| Manager, SEC Reporting | Berkeley Heights, NJ | Aug 25, 2026 | Oct 5, 2026 | Mid |
| Scientist II, In-Vitro & Nonclinical Assay Development | Frederick, MD | Aug 21, 2026 | Oct 5, 2026 | Mid |
| Associate Director, Commercial Analytics & Sales Force Effectiveness | Berkeley Heights, NJ | Aug 6, 2026 | Oct 5, 2026 | Senior |
| Manager, Commercial Analytics & Reporting | Berkeley Heights, NJ | Jul 24, 2026 | Oct 5, 2026 | Mid |
| VP, Translational Science (Nonclinical) Development | Berkeley Heights, NJ, or Frederick, MD | Jul 15, 2026 | Oct 5, 2026 | Executive |
Funding
- Follow-on offering — Registered direct: $20M (total, as published), announced Dec 29, 2025. Source: company release on GlobeNewswire. source ↗
Clinical trials (lead sponsor) 34
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT07621237 | A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) | Phase 2 | Recruiting | Jun 25, 2026 | 2028-02 (estimated) |
| NCT07473752 | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects | 1 | Completed | Jul 18, 2023 | Feb 22, 2024 (actual) |
| NCT07464535 | A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects | Phase 1 | Completed | Mar 18, 2022 | Apr 30, 2022 (actual) |
| NCT07413367 | A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants | 1 | Active, not recruiting | Dec 9, 2025 | Feb 10, 2026 (estimated) |
| NCT06045793 | Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) | Phase 2 | Terminated | Aug 16, 2024 | Apr 21, 2025 (actual) |
| NCT05679908 | A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine | Phase 2 | Completed | Dec 6, 2022 | Oct 8, 2023 (actual) |
| NCT02829814 | Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia | Phase 3 | Terminated | Jul 22, 2016 | Sep 13, 2016 (actual) |
| NCT02589275 | A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients | Phase 3 | Completed | Aug 4, 2015 | Sep 28, 2016 (actual) |
| NCT05686408 | Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) | Phase 2 | Completed | Mar 2, 2023 | Sep 29, 2023 (actual) |
| NCT02436096 | A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia | Phase 3 | Completed | 2015-04 | 2016-09 (actual) |
| NCT03110575 | 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients | Phase 3 | Terminated | Jun 20, 2017 | Jul 27, 2018 (actual) |
| NCT03841773 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD | 3 | Terminated | Mar 7, 2019 | Apr 24, 2020 (actual) |
| NCT02421679 | Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions | Phase 2 | Completed | Apr 14, 2015 | May 26, 2016 (actual) |
| NCT03508700 | A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD | Phase 3 | Completed | Apr 19, 2018 | Sep 30, 2019 (actual) |
| NCT05273749 | A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia | 3 | Completed | Apr 6, 2022 | Nov 14, 2023 (actual) |
| NCT05472090 | A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection | 2 | Completed | Aug 18, 2022 | Jul 12, 2023 (actual) |
| NCT05216510 | Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens | Phase 1 | Terminated | Jan 7, 2022 | Sep 17, 2022 (actual) |
| NCT02277704 | Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions | Phase 2 | Completed | 2014-10 | 2016-05 (actual) |
| NCT03062540 | Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD | Phase 3 | Terminated | Mar 27, 2017 | Jul 27, 2018 (actual) |
| NCT04508621 | A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | 3 | Completed | Jul 22, 2020 | Nov 1, 2021 (actual) |
| NCT05372887 | Safety and Efficacy Study of TNX-102 SL in Participants With PTSD | Phase 2 | Withdrawn | Oct 14, 2022 | Nov 8, 2022 (actual) |
| NCT04172831 | A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia | Phase 3 | Completed | Dec 9, 2019 | Oct 29, 2020 (actual) |
| NCT04996056 | An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects | Phase 2 | Withdrawn | Sep 3, 2021 | Jun 16, 2022 (actual) |
| NCT04164719 | Dose-Proportionality and Food Effect Study of TNX-102 SL | Phase 1 | Completed | Oct 14, 2019 | Dec 24, 2019 (actual) |
| NCT01490788 | A Comparative Bioavailability and Pharmacokinetic Study of TNX-102 2.4 mg and Cyclobenzaprine 5 mg Tablets in Healthy Adults. | Phase 1 | Completed | Nov 18, 2011 | Dec 30, 2011 (actual) |
| NCT03168022 | Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers. | Phase 1 | Completed | Dec 16, 2015 | Jan 26, 2016 (actual) |
| NCT03443960 | Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules | Phase 1 | Completed | Jan 29, 2018 | Apr 9, 2018 (actual) |
| NCT02015234 | 12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients | Phase 3 | Completed | 2013-12 | 2015-08 (actual) |
| NCT02423408 | Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache | Phase 2 | Completed | 2015-06 | 2016-02 (actual) |
| NCT01903265 | BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) | Phase 2/Phase 3 | Completed | 2013-09 | 2014-07 (actual) |
| NCT02290379 | Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers | 1 | Completed | 2014-11 | 2015-05 (actual) |
| NCT01689259 | Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults | Phase 1 | Completed | 2012-09 | 2013-12 (actual) |
| NCT01889173 | Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults | Phase 1 | Completed | 2013-06 | 2013-12 (actual) |
| NCT01634412 | Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults | Phase 1 | Completed | 2012-06 | 2013-09 (actual) |
FDA records (last 2 years)
- FDA Original approval: TONMYA (cyclobenzaprine hydrochloride) — NDA219428, Aug 15, 2025. Applicant at approval: Tonix Pharmaceuticals, Inc. source ↗
Connect
See your connections at Tonix Pharmaceuticals on LinkedIn (search by name, results not checked)